ArticleCHEST pulmonary2025
Contribution of Interstitial Lung Disease to Mortality in Patients With Connective Tissue Diseases.
Article in CHEST pulmonary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interstitial lung diseases (ILDs) are common in patients with connective tissue diseases (CTDs), but their role in the mortality of patients with CTDs remains unexplored. Research Question: What proportion of mortality in patients with CTDs is due to ILD? Study Design and Methods: In this retrospective, population-based epidemiologic study, we used the Wide-Ranging Online Data for Epidemiologic Research database and extracted mortality data of all deceased US citizens aged ≥ 15 years, from 1999 to 2019. Age-adjusted mortality rate (AAMR) was calculated by sex, racial group, and state of death. The annual trend was examined using the annual percent change and average annual percent change. We identified the rank of ILD as an underlying cause of death compared with the 15 leading causes of death in patients with CTDs. Results: From 1999 to 2019, CTDs were mentioned in the death certificates of 286,643 US citizens, with 26,406 (7.12%) of them having ILDs simultaneously. The ILD-CTD-related AAMR per 1 million population decreased from 4.26 in 1999 to 3.37 in 2015 and further increased to 4.03 in 2019. The ILD-CTD-related AAMRs during 1999 to 2019 for female individuals and male individuals were 4.53 and 2.80 per 1 million, respectively. In the list of 15 leading causes of mortality, ILD could be ranked as the seventh, 11th, third, fourth, and fourth cause of death in patients with rheumatoid arthritis, systemic lupus erythematosus, polymyositis/dermatomyositis, systemic sclerosis, and Sjögren syndrome, respectively. Interpretation: Our findings underscore the necessity for developing screening protocols and targeted interventions aimed at reducing ILD-related mortality in patients with CTD. This could significantly improve outcomes and quality of life for these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.